The impending Supreme Court ruling on gene patents is creating uncertainty in the molecular diagnostics sector.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
A startup called Catabasis is developing drugs that hit diseases at multiple targets.
An easy-to-use EEG cap could expand the number of ways to interact with your mobile devices.
Mice tap into their own neural reward circuits with the help of a new optogenetics device.
Obama calls for $100 million to develop new technologies to understand the brain.
A microfluidic device that captures circulating tumor cells could give doctors a noninvasive way to diagnose and track cancers.
New partnerships could help bring a novel class of biopharmaceutical to patients.
An RFID-reading, motion-sensing wristband buzzes to tell health-care workers if they are washing their hands properly.
By monitoring the path of stem cells in the body, scientists can better explore experimental therapies, and doctors can better tune treatments in patients.